` 688351 (Shanghai MicroPort EP Medtech Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

S
688351
vs
S
Shanghai Composite

Over the past 12 months, Shanghai MicroPort EP Medtech Co Ltd has underperformed Shanghai Composite, delivering a return of +22% compared to the Shanghai Composite's +23% growth.

Stocks Performance
688351 vs Shanghai Composite

Loading
688351
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
688351 vs Shanghai Composite

Loading
688351
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
688351 vs Shanghai Composite

Loading
688351
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Shanghai MicroPort EP Medtech Co Ltd vs Peers

Shanghai Composite
688351
LEG
PMT
DFS
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shanghai MicroPort EP Medtech Co Ltd
Glance View

Market Cap
11B CNY
Industry
Health Care

Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.

Intrinsic Value
10.79 CNY
Overvaluation 54%
Intrinsic Value
Price
S
Back to Top